Recently, Zu Xiongbing, Visiting Professor of Urology at the First Affiliated Hospital of University of South China, led his team in publishing high-impact research findings on immune resistance in bladder cancer in the internationally renowned journal Journal of Hematology & Oncology (CAS Q1, TOP journal, Impact Factor: 29.5). Professor Zu served as the senior corresponding author, with Dr. Kuang Xiaogen from the hospital’s Department of Urology as co-corresponding author,the First Affiliated Hospital of University of South China as a co-corresponding institution.
This study builds upon the team’s previous work published in Theranostics (CAS Q1, TOP journal, Impact Factor: 12.4), titled “Siglec15 shapes a non-inflamed tumor microenvironmentpredicts the molecular subtype in bladder cancer.” Through comprehensive analysis of multiple clinical cohorts, including the “Xiangya Cohort” for bladder cancer established under Professor Zu’s leadership, the study identifieddemonstrated the role of Siglec15 in reshaping the non-inflamed immune microenvironment in bladder cancer, as well as its potential to predict immunotherapy responsepatient prognosis. The research further conducted extensive multi-omics correlation analyses of Siglec15, providing preliminary evidence supporting its value as an immunotherapeutic target in bladder cancer.
The newly published study in the Journal of Hematology & Oncology, titled “Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer,” comprehensively explains the rolemechanisms of Siglec15 in bladder cancer through multi-dimensionalin-depth analyses. By integrating cellular functional studies, molecular biology,tissue morphology using in vitro, in vivo,clinical samples, the study reveals how Siglec15 reshapes the tumor immune microenvironmentpromotes resistance to immunotherapy. These findings provide a theoretical foundation for the development of novel immunotherapeutic targetspredictive biomarkers for bladder cancer.
Professor Zuhis researchinnovation team have long been dedicated to the diagnosis, treatment, basic research,translational studies of urological tumors, including bladder cancerprostate cancer. Aiming to improve patient careidentify new therapeutic targets, the team has published over 80 research papers on bladder cancer treatmentimmune resistance. These include more than 60 papers in high-impact SCI journals such as European Urology (IF = 24.3), Journal of Hematology & Oncology (IF = 29.5), Cell Reports Medicine (IF = 14.3), Nature Reviews Urology (IF = 12.9), Advanced Science (IF = 15.1), Journal for Immunotherapy of Cancer (IF = 11.0), Theranostics (IF = 11.5), BMC Medicine (IF = 11.8), EMBO Reports (IF = 8.8),Oncogene (IF = 9.8), with six papers recognized as ESI Highly Cited Papers.
Professor Zu has led six projects on bladder disease funded by the National Natural Science Foundation of China (NSFC). He has also received multiple awards, including the Second Prize of the Hunan Provincial ScienceTechnology Progress Awardthe First Prize of the Hunan Medical ScienceTechnology Award. He serves as Associate Editoreditorial board member for several SCI-indexed journals, including Gland Surgery and Frontiers in Oncology.